Oncternal Therapeutics, founded as a clinical-stage oncology company, is dedicated to developing innovative treatments for cancers with significant unmet medical needs. The company's core mission is to advance a diverse pipeline of therapies targeting hematological malignancies and solid tumors, including prostate cancer. Oncternal leverages multiple modalities to address these critical health challenges, aiming to improve patient outcomes and quality of life.
Notable figures associated with Oncternal Therapeutics include experienced leaders in oncology and biotech sectors. The company has achieved key milestones, such as completing enrollment and initiating dosing for its Phase 1/2 study of ONCT- for metastatic castration-resistant prostate cancer. Oncternal's impact is marked by its commitment to addressing pressing cancer treatment gaps, contributing to the advancement of oncology therapeutics.
